ADVANCING THE EVIDENCE BASE FOR CARE AND POLICY IN PRIORITY HEALTH AREAS
Funder
National Health and Medical Research Council
Funding Amount
$11,195,727.00
Summary
This program will improve health care and policy through clinical trials research and better methods for combining trial evidence. The team will tackle priority health areas to reduce death and serious disability: in particular in cancer, cardiovascular disease, diabetes, obesity and neonatal diseases. The program team includes clinicians, epidemiologists, trialists, biostatisticians, and health economists and collaborative networks of clinical investigators in each disease area.
Improving Stroke Outcomes: Attenuating Progression And Recurrence
Funder
National Health and Medical Research Council
Funding Amount
$9,331,996.00
Summary
Stroke is the second most common cause of death and major cause disability. There are few proven interventions, so we need to introduce new ones. We developed a bench to bedside program to introduce new stroke therapies and its early secondary prevention. Our general goal is to provide evidence for their effectiveness and safety. We will use animal stroke models, markers in the blood to help diagnose and predict stroke outcome and imaging to help select patients for several clinical trials.
Clinical, Public Health And Policy Interventions To Combat Cardiovascular Diseases
Funder
National Health and Medical Research Council
Funding Amount
$24,025,090.00
Summary
This program will generate and translate evidence from high-quality research designed to inform the decisions of health care providers and policy makers about best strategies for the prevention and treatment of cardiometabolic conditions. The program, with both domestic and global relevance, will address a spectrum of issues, with translational outcomes for clinical research.
STEP: Improving The Evaluation And Use Of Tests For Screening, Diagnosis And Monitoring In Healthcare.
Funder
National Health and Medical Research Council
Funding Amount
$9,566,865.00
Summary
Medical tests - for screening, diagnosis, and monitoring - are often poorly evaluated and poorly used. This program, run by an established team with skills in public health, clinical epidemiology, biostatistics, health economics and behavioural science, addresses the under-researched issues of whether, when and how to use medical tests. The elements of the program follow the sequence in which testing is often done: for screening (early detection), for diagnosis on which to base treatment decisio ....Medical tests - for screening, diagnosis, and monitoring - are often poorly evaluated and poorly used. This program, run by an established team with skills in public health, clinical epidemiology, biostatistics, health economics and behavioural science, addresses the under-researched issues of whether, when and how to use medical tests. The elements of the program follow the sequence in which testing is often done: for screening (early detection), for diagnosis on which to base treatment decisions, and for monitoring the effects of treatment. A common approach throughout is the identification of the benefits and harms of testing and assessing their trade-offs; how benefits weigh up against harms. This research is relevant to all partners in healthcare - consumers, clinicians and policymakers - who currently are being tested or implementing tests without being fully informed about the accuracy and effects of these tests.Read moreRead less
Drug-related deaths in Australia account for 6.6% of all deaths (ABS 2009). In much of the rural Asia-Pacific, pesticide poisoning and snakebite are major problems. We propose an integrated and international human toxicology research program covering medicine and chemical poisoning, serious adverse drug reactions, snake and spider bite. Our focus is on the applied research needed to detect new problems and rapidly translate early findings into better treatment, regulations & policy.